Arena Analyst Call Adds Little To Lorcaserin Dialog
This article was originally published in The Pink Sheet Daily
Executive SummaryThe biotech adds little clarity to the situation surrounding the rejection of its obesity drug lorcaserin by FDA in a conference call with stakeholders.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.